Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on immune dysregulation and inflammatory disease. Its lead program is AVTX-009, an anti-IL-1β monoclonal antibody being developed for hidradenitis suppurativa and potentially other immune-mediated indications. The company is still in the development phase and does not yet have commercial product revenue, so its value is tied primarily to clinical execution, regulatory progress, and business development optionality. Avalo also evaluates opportunities to out-license programs, indications, or geographies as part of its path to value creation.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment of AVTX-009 and related clinical-stage work in immune-mediated disease.
Sponsor-led execution of the LOTUS Phase 2 trial across multiple countries.
Out-licensing, in-licensing, and partnering activities for programs and geographies.
Customers
Avalo does not sell commercial medicines today; its primary counterparties are clinical trial participants, investigators, and trial sites that support AVTX-009 development. In a broader business sense, the company’s future customers would be physicians, hospitals, and patients in immune-mediated disease markets if a product is approved. The company also depends on pharmaceutical partners and licensees that may acquire rights to indications or geographies through out-licensing transactions. Because the business is pre-revenue and development-stage, investor and partner confidence in the clinical data package is central to its ability to attract funding and collaborations.
Adults with moderate to severe hidradenitis suppurativa enrolled to evaluate AVTX-009 safety and efficacy.
Hospitals, clinics, and research centers that execute the LOTUS protocol and generate the data package.
Companies that may license AVTX-009 rights, fund development, or collaborate on specific indications or regions.
Dermatology and immunology stakeholders who would use the product if it reaches approval and commercialization.
Strategy
Avalo’s near-term strategy is to advance AVTX-009 through the Phase 2 LOTUS trial and prepare for the next stage of development in hidradenitis suppurativa. Management also wants to evaluate indication expansion for AVTX-009, which could broaden the commercial opportunity if the asset shows clinical promise. A second strategic pillar is business development: the company may out-license rights to compounds, indications, or geographies, or pursue strategic alliances and asset sales. Because the company remains pre-commercial, preserving cash runway while creating optionality through clinical milestones is central to its strategy.
Clinical data is the main value driver for a pre-commercial biotech and determines whether the asset can progress or be partnered.
A broader label opportunity can increase the asset’s commercial value and improve partnering leverage.
Non-dilutive capital and shared development risk are important for a company with ongoing operating losses.
Geography
Avalo’s current operating footprint is centered in the United States, where it is headquartered and where a meaningful portion of its clinical and corporate activity is managed. The LOTUS Phase 2 trial is multinational, with sites in North America, Europe, and Australia, which broadens patient access but also increases operational complexity. The company specifically cites trial locations in the United States, Canada, France, Germany, Italy, Spain, Bulgaria, Czech Republic, Greece, Poland, Australia, Turkey, and Slovakia. Because the company is still in development, geography matters mainly through clinical execution, regulatory coordination, and the ability to expand or out-license rights by region.
Risks
Avalo’s biggest risk is clinical development failure, since the company’s value depends heavily on AVTX-009 and the LOTUS trial outcome. As a pre-revenue biotech, it also faces financing risk: if capital markets weaken or partnering terms are unattractive, the company may need to dilute shareholders or give up valuable rights. Regulatory risk is material because even promising data may not translate into FDA or foreign approval, and trial design, endpoint selection, and safety findings can all affect the path forward. More generally, biotech companies face high R&D burn, trial enrollment delays, competitive therapies in inflammatory disease, and uncertainty around whether a single asset can support a durable commercial franchise.
The company’s near-term value creation is concentrated in a single lead asset and one key Phase 2 study.
Exposure: Clinical development and pipeline concentration
Avalo has a history of operating and cash losses and may need equity or partnering capital to fund development.
Exposure: Liquidity and capital markets
Positive clinical results do not guarantee FDA or ex-U.S. approval, and the approval path may require additional studies.
Exposure: FDA and foreign regulatory agencies
Multinational trials depend on site activation, patient recruitment, and protocol adherence across many countries.
Exposure: Trial operations
Competing biologics and emerging therapies could reduce the commercial opportunity even if AVTX-009 succeeds.
Exposure: Hidradenitis suppurativa and inflammatory disease markets
Accounting
Judgemental itemsTrial-related costs are estimated before invoices are finalized, affecting R&D expense timing and quarterly comparability.
Impact: Can shift reported operating loss between periods
Changes in valuation assumptions can create large non-cash gains or losses in other income/expense.
Impact: Can materially distort net income or loss
Equity awards are a recurring cost for a development-stage company and affect operating expense and dilution analysis.
Impact: Raises reported expenses without immediate cash outflow
Any upfront fees, milestones, or royalties from out-licensing would require careful contract accounting.
Impact: Could create lumpy revenue recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
Evommune, Inc.
EVMN · Pharmaceutical Preparations
Apollomics Inc.
APLMW · Pharmaceutical Preparations
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
Alvotech
ALVO · Biological Products, (No Diagnostic Substances)
Alvotech is a U.S.-listed biotechnology company focused on developing and manufacturing biosimilar medicines.
BioAtla, Inc.
BCAB · Biological Products, (No Diagnostic Substances)
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026